Selank Where to Buy: The Batch Decides the Testing

Summary: A buying framework for a peptide with no approved medical route anywhere in the West, applied honestly to the vendor we link, including which of its certificates you actually need to open.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Selank where to buy is a documentation question, and the honest version of the answer starts with something most pages selling it will not tell you: there is no medically supervised route to this compound anywhere in the United States, so every criterion below is one you have to apply yourself.

The listing this page keeps testing its own checklist against is here, so you can open the documents alongside the argument.

Before anything else, Selank is not a GLP-1

Most people reading this site are on semaglutide or tirzepatide, or deciding whether to be. Selank arrived in your feed from the same forums and it belongs to a completely different category, so the comparison you are carrying over probably does not transfer.

Selank is a synthetic heptapeptide, seven amino acids in the order Thr-Lys-Pro-Arg-Pro-Gly-Pro ^[3]. The first four residues are tuftsin, a naturally occurring immune peptide, and the Pro-Gly-Pro tail on the end is there to slow the enzymes that would otherwise take it apart in minutes. It was developed at the Institute of Molecular Genetics in Russia and carries a Russian registration as an anxiolytic. It has a molecular formula of C33H57N11O9 and a molecular weight of 751.9 ^[3].

It has no incretin activity. It does not act on the GLP-1 receptor, does not slow gastric emptying, and has no weight-loss indication anywhere in the world. If it has been sold to you as something that pairs with a GLP-1, the pairing is a marketing idea rather than a pharmacological one.

The evidence gap is the part worth sitting with. The medications this site covers arrived through large randomized trials with pre-registered endpoints and published results. Selank did not. What exists in the English-language literature is largely animal work: rats given Selank in a morphine withdrawal model ^[5], studies of hippocampal neuron activity in rat brain slices, ethanol-related behavioural work in mice. Those are hypothesis-generating experiments in animals. They are not the same class of evidence, and no amount of confident copywriting converts one into the other.

The regulatory position, which almost every competing page reports incorrectly

If you search this compound you will quickly find pages stating that Selank is "FDA Category 2" or "banned from compounding". That is out of date, and understanding why is genuinely useful rather than pedantic.

FDA sorts bulk drug substances nominated for compounding under section 503A into three categories. Selank appears in none of them. Search the current category lists, updated May 14, 2026, and the word does not appear ^[2].

Where it does appear is on a separate FDA page, under the heading "Bulk drug substances nominated but withdrawn". FDA introduces that list as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators" ^[1]. So the pages saying Category 2 are not inventing it. They are quoting a snapshot that has since moved. The accurate statement today is that Selank acetate was nominated, spent time in Category 2, the nomination was withdrawn, and it now sits on no current list at all.

Current 503A Category 2 contains exactly six substances: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration ^[1]. Selank is not among them.

None of that is approval. There is no FDA-approved Selank product for any indication, and the Russian registration is a different regulator applying a different standard, not a fact about the American market.

The sentence from FDA that should shape what you buy

The withdrawn-nomination page still records what FDA thought the risk was, and it is specific rather than generic:

Read that as a buyer rather than as a regulator. Immunogenicity means your immune system reacting to the material. The two causes FDA names are aggregation, where peptide molecules clump into larger structures the body reads as foreign, and peptide-related impurities, meaning the truncated and modified versions of the sequence that synthesis leaves behind. Both are manufacturing and handling problems. Both are measurable.

That converts a vague safety worry into two concrete things to look for on paper: a purity figure that tells you how much of the powder is the intended sequence, and, for anything that will end up in solution and cross a membrane, an endotoxin result. Those are separate tests answering separate questions, and the second one is the one this market routinely omits on older batches.

Selank where to buy: the criteria, hardest first

The order matters. A supplier can be excellent on the bottom four rows and still be the wrong purchase if it fails the top two.

None of this requires a chemistry background. All of it requires opening a PDF instead of reading a landing page, which is precisely the step most buyers skip.

Scoring the source we link, including the row that turns on the batch

We link Ascension Peptides and we earn a commission if you buy through the card above, which is disclosed there and in our disclaimer. That is the reason to run the checklist strictly rather than gently.

The product is Selank 10 mg. List price is $47.50, reduced from $60.00, and the code PEPTIDEDECK takes it to $23.75, which is $2.38 per milligram. Buying 3, 5 or 10 vials takes 3%, 5% or 10% off the list price as a separate mechanism, and free shipping starts at $250. Stock is domestic with a same-day cutoff, and the listing is labelled for laboratory research only with no human-use claims attached.

On the documentation rows, open the certificates yourself, and note the plural. The product page carries more than one, and the one that is a clickable link is the older and thinner of them. That linked file ^[4] is issued by MZ Biolabs in Tucson, Arizona, on lot 29-01260229, analysis date 2026-02-07, and it is already better than most of this market publishes:

• Purity 99.32% by HPLC-UV, with the chromatogram printed and a peak list showing two detected peaks, the minor one at 0.68%.
• Identity by mass spectrometry, expected monoisotopic mass 751.43 Da against a measured 751.47 Da.
• Measured quantity of 12.29 mg in a vial labelled 10 mg.

That third line deserves a moment, because publishing an independently measured fill weight is unusual and it happens to be in the buyer's favour here. Treat it as a fact about one lot rather than a promise about yours. A vendor that prints a number that could have embarrassed it is telling you something about how it handles documents.

Now the row that file fails. There is no endotoxin test on the February certificate. No LAL assay, no pyrogen result, no sterility screen, nothing addressing the exact category of risk FDA named. We checked the document rather than assuming.

Then open the other certificate on the same page. Batch 29-05260628, certified 2 June 2026 by Kovera, carries a bacterial endotoxin test by kinetic chromogenic LAL to USP Chapter 85, reported below 0.20 EU/mL against a 0.5 EU/mL limit, a rapid sterility screen returning no growth, and a heavy metals panel. The row that fails on one document passes on the other, and the two describe different batches of the same product. Treat the sterility line carefully even so: the report calls it a rapid screen and notes that full USP Chapter 71 testing may be required for regulatory compliance, so it is not a sterility guarantee.

That is the most useful thing on this page. Not a verdict on the seller, but a batch number to match, which costs about a minute and decides whether the assay FDA's concern is about was ever run on your vial.

Where this leaves a realistic buyer

If you want a supervised route, there is not one. No prescriber can write for Selank in the United States, because there is no approved product to prescribe and no current category listing that would let a compounding pharmacy prepare it. The situation is closer to the research-vial market we describe in how to judge a BPC-157 supplier yourself than to anything in our GLP-1 coverage, and the same discipline applies.

The endotoxin question specifically is one we have worked through in more depth on the NAD+ side, where FDA published a direct warning about it, and the grade and testing argument on the NAD+ buying page is worth reading if you want the reasoning rather than the conclusion.

And if you want to see what the other end of the evidence spectrum looks like, the retatrutide clinical trial record is a useful calibration. That is what a dossier looks like when a compound has actually been studied in people at scale. Selank has nothing of that shape behind it, and pretending otherwise is the single most common failure in the pages that rank for this query.

Questions people ask before ordering

Is Selank approved or legal to buy?

There is no FDA-approved Selank product for any indication. It is sold in the United States as a research chemical, which is a lawful category for sale and possession but explicitly not for human use. Its Russian anxiolytic registration is a different regulator's decision and does not carry over.

Is Selank on the FDA Category 2 list?

No, and this is the most common error in pages covering it. Selank acetate was nominated and spent time in Category 2, then the nomination was withdrawn by the nominators. It appears on no current 503A category list. Pages saying otherwise are citing a snapshot that has moved.

What does the certificate actually prove?

Ask which certificate first, because the product page carries two. The linked February one, lot 29-01260229, proves the powder is 99.32% pure by HPLC-UV, is the right molecule by mass spectrometry against an expected 751.43 Da, and held 12.29 mg. It says nothing about endotoxins. The June batch, 29-05260628, adds the endotoxin result, a rapid sterility screen and heavy metals. Whichever you read proves things about that batch only.

Why does endotoxin testing keep coming up?

Because it is the one thing FDA specifically flagged, in the form of immunogenicity risk from aggregation and peptide-related impurities, and because purity testing does not detect it. Endotoxins are bacterial cell wall fragments that survive sterilisation and need their own assay.

Can a compounding pharmacy make Selank for me?

Not under the interim policies. A compounder relies on a substance appearing in Category 1 to have FDA's stated non-enforcement position. Selank appears in no category, so there is no pathway of that kind, which is different from the situation for some other compounds this site covers.

Does the nasal spray format change any of this?

It changes the sterility expectations rather than the regulatory position. Ascension sells a lyophilised vial, not a spray. The consumer spray market is a separate set of sellers with generally thinner documentation, and none of it is FDA approved either.

Selank where to buy comes down to a market that sells documents as much as it sells powder, and the document answering FDA's stated concern exists for some batches and not others. The vendor we link publishes more than most, and its June 2026 batch carries the endotoxin and sterility lines its February one does not. So the decisive question is not which seller but which batch. Read every certificate on the page before you order, and let the batch number count.